nach oben

Journal of Assisted Reproduction and Genetics

Erschienen in:

22.06.2022 | Review

Ovulation induction and intrauterine insemination in women of advanced reproductive age: a systematic review of the literature

verfasst von: Carleigh B. Nesbit, Misty Blanchette-Porter, Navid Esfandiari

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this review is to define live birth rate (LBR) and clinical pregnancy rate (CPR) for women ≥ 40 undergoing ovulation induction (OI)/intrauterine insemination (IUI).

Methods

A systematic review was performed in accordance with PRISMA guidelines using PubMed and Google Scholar. The primary and secondary outcomes of interest were LBR and CPR, respectively.

Results

There were 636 studies screened of which 42 were included. In 8 studies which provided LBR for partner sperm, LBR/cycle ranged from 0 to 8.5% with majority being ≤ 4%. Cumulative LBR was 3.6 to 7.1% over 6 cycles with the majority of pregnancies in the first 4. In the four studies providing LBR for donor sperm cycles, LBR/cycle ranged from 3 to 7% with cumulative LBR of 12 to 24% over 6 cycles. The majority of pregnancies occurred in the first 6 cycles. There were three studies with LBR or CPR/cycle ≥ 1% for women ≥ 43. No studies provided data above this range for women ≥ 45. In 4 studies which compared OI/IUI and IVF, the LBR from IVF was 9.2 to 22% per cycle. In 7 studies which compared outcomes by stimulation protocol, no significant differences were seen.

Conclusion

For women ≥ 40 using homologous sperm, the highest probability of live birth is via IVF. However, if IVF is not an option, OI/IUI may be considered for up to 4 cycles in those using partner sperm or 6 cycles with donor sperm. For women > 45, OI/IUI is likely futile but a limited trial may be considered for psychological benefit while encouraging consideration of donor oocyte IVF or adoption. Use of gonadotropins does not appear to be more effective than oral agents in this age group.

Allahbadia G. Intrauterine insemination: fundamentals revisited. J Obstet Gynaecol India. 2017. https://doi.org/10.1007/s13224-017-1060-x.CrossRefPubMedPubMedCentral

Cheung L. Patient selection for assisted reproductive technology treatments. Hong Kong Med J. 2000;6:177–83.PubMed

Dodson WC, Haney AF. Controlled ovarian hyperstimulation and intrauterine insemination for treatment of infertility. Fertil Steril. 1991. https://doi.org/10.1016/S0015-0282(16)54168-5.CrossRefPubMed

American Society for Reproductive Medicine (ASRM). Evidence-based treatments for couples with unexplained infertility: a guideline. Fertil Steril. 2020. https://doi.org/10.1016/j.fertnstert.2019.10.014.CrossRef

Schlegel PN, Sigman M, Collura B, De Jonge CJ, Eisenberg ML, Lamb DJ, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II. J Urol. 2021. https://doi.org/10.1097/JU.0000000000001520.CrossRefPubMed

American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 586: Health disparities in rural women. Obstet Gynecol. 2014; https://doi.org/10.1097/01.AOG.0000443278.06393.d6.

American Society for Reproductive Medicine (ASRM). Disparities in access to effective treatment for infertility in the United States: an Ethics Committee Opinion. Fertil Steril. 2021. https://doi.org/10.1016/j.fertnstert.2015.07.1139.CrossRef

Harris JA, Menke MN, Haefner JK, Moniz MH, Perumalswami CR. Geographic access to assisted reproductive technology health care in the United States: a population-based cross-sectional study. Fertil Steril. 2017. https://doi.org/10.1016/j.fertnstert.2017.02.101.CrossRefPubMed

American College of Obstetricians and Gynecologists (ACOG) and American Society for Reproductive Medicine (ASRM). Committee Opinion No. 589: age related fertility decline. Fertil Steril. 2014; https://doi.org/10.1016/j.fertnstert.2013.12.032

10.

Broekmans FJ, Klinkert ER. Female age in ART: when to stop? Gynecol Obstet Invest. 2004. https://doi.org/10.1159/000080794.CrossRefPubMed

11.

O’Connor KA, Holman DJ, Wood JW. Declining fecundity and ovarian ageing in natural fertility populations. Am J Human Biol. 1998. https://doi.org/10.1016/s0378-5122(98)00068-1.CrossRef

12.

Schwartz D, Mayaux MJ. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. N Engl J Med. 1982. https://doi.org/10.1056/NEJM198202183060706.CrossRefPubMed

13.

Armstrong S, Akande V. What is the best treatment option for infertile women aged 40 and over? J Assist Reprod Genet. 2013. https://doi.org/10.1007/s10815-013-9980-6.CrossRefPubMedPubMedCentral

14.

Cabry R, Merviel P, Hazout A, Belloc S, Dalleac A, Copin H, et al. Management of infertility in women over 40. Maturitas. 2014. https://doi.org/10.1016/j.maturitas.2014.02.014.CrossRefPubMed

15.

Liu K, Case A. Advanced reproductive age and fertility. J Obstet Gynaecol Can. 2011. https://doi.org/10.1016/S1701-2163(16)35087-3.CrossRefPubMed

16.

Ludwig AK, Diedrich K, Ludwig M. The process of decision-making in reproductive medicine. Semin Reprod Med. 2005. https://doi.org/10.1055/s-2005-923392.CrossRefPubMed

17.

Marinakis G, Nikolaou D. National survey of the current management of infertility in women aged 40 and over in the UK. Obstet Gynaecol. 2012. https://doi.org/10.3109/01443615.2012.663424.CrossRef

18.

Tsafrir A, Simon A, Margalioth EJ, Laufer N. What should be the first-line treatment for unexplained infertility in women over 40 years of age-ovulation induction and IUI or IVF? Reprod Biomed Online. 2009;19:4334.CrossRef

19.

Maxwell E, Mathews M, Mulay S. The impact of access barriers on fertility treatment decision making: a qualitative study from the perspectives of patients and service providers. Obstet Gynaecol Can. 2018. https://doi.org/10.1016/j.jogc.2017.08.025.CrossRef

20.

Weigel G, Ranji U, Long M, Salganicoff A. Coverage and use of fertility services in the U.S. Kaiser family foundation website. Accessed Sep 4, 2021. https://www.kff.org/womens-health-policy/issue-brief/coverage-and-use-of-fertility-services-in-the-u-s/.

21.

American Society for Reproductive Medicine (ASRM). Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion. Fertil Steril. 2019. https://doi.org/10.1016/j.fertnstert.2019.01.033.CrossRef

22.

Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009. https://doi.org/10.1371/journal.pmed.1000097.CrossRefPubMedPubMedCentral

23.

Haebe J, Martin J, Tekepety F, Tummon I, Shepherd K. Success of intrauterine insemination in women aged 40–42 years. Fertil Steril. 2002. https://doi.org/10.1016/S0015-0282(02)03168-0.CrossRefPubMed

24.

Agarwal SK, Buyalos RP. Clomiphene citrate with intrauterine insemination: is it effective therapy in women above the age of 35 years? Fertil Steril. 1996. https://doi.org/10.1016/s0015-0282(16)58210-7.CrossRefPubMed

25.

Dovey S, Sneeringer RM, Penzias AS. Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles. Fertil Steril. 2008. https://doi.org/10.1016/j.fertnstert.2007.10.057.CrossRefPubMed

26.

Ferrara I, Balet R, Grudzinskas JG. Intrauterine insemination with frozen donor sperm. Pregnancy outcome in relation to age and ovarian stimulation regime. Hum Reprod. 2002. https://doi.org/10.1093/humrep/17.9.2320.CrossRefPubMed

27.

Gomez R, Schorsch M, Steetskamp J, Hahn T, Heidner K, Seufert R, et al. The effect of ovarian stimulation on the outcome of intrauterine insemination. Arch Gynecol Obstet. 2014. https://doi.org/10.1007/s00404-013-2952-3.CrossRefPubMed

28.

Steiner N, Ruiter-Ligeti J, Frank R, Al Shatti M, Badeghiesh A, Rotshenker-Olshinka K, et al. Do oral ovulation induction agents offer benefits in women 38 to 43 years of age undergoing insemination cycles? Eur J Obstet Gynecol Reprod Biol. 2021. https://doi.org/10.1016/j.ejogrb.2021.01.012.CrossRefPubMed

29.

Van Der Westerlaken LA, Naaktgeboren N, Helmerhorst FM. Evaluation of pregnancy rates after intrauterine insemination according to indication, age, and sperm parameters. J Assist Reprod Genet. 1998. https://doi.org/10.1023/A:1022576831691.CrossRefPubMedPubMedCentral

30.

Wiser A, Shalom-Paz E, Reinblatt SL, Son WY, Das M, Tulandi T, et al. Ovarian stimulation and intrauterine insemination in women aged 40 years or more. Reprod Biomed Online. 2012. https://doi.org/10.1016/j.rbmo.2011.11.007.CrossRefPubMed

31.

Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R. Effect of diagnosis, age, sperm quality, and number of preovulatory follicles on the outcome of multiple cycles of clomiphene citrate-intrauterine insemination. Fertil Steril. 2002. https://doi.org/10.1016/s0015-0282(02)04212-7.CrossRefPubMed

32.

Brzechffa PR, Buyalos RP. Female and male partner age and menotrophin requirements influence pregnancy rates with human menopausal gonadotrophin therapy in combination with intrauterine insemination. Hum Reprod. 1997. https://doi.org/10.1093/humrep/12.1.29.CrossRefPubMed

33.

Harris ID, Missmer SA, Hornstein MD. Poor success of gonadotropin-induced controlled ovarian hyperstimulation and intrauterine insemination for older women. Fertil Steril. 2010. https://doi.org/10.1016/j.fertnstert.2009.02.040.CrossRefPubMed

34.

Soares SR, Cruz M, Vergara V, Requena A, García-Velasco JA. Donor IUI is equally effective for heterosexual couples, single women and lesbians, but autologous IUI does worse. Hum Reprod. 2019. https://doi.org/10.1093/humrep/dez179.CrossRefPubMed

35.

Merviel P, Heraud MH, Grenier N, Lourdel E, Sanguinet P, Copin H. Predictive factors for pregnancy after intrauterine insemination (IUI): an analysis of 1038 cycles and a review of the literature. Fertil Steril. 2010. https://doi.org/10.1016/j.fertnstert.2008.09.058.CrossRefPubMed

36.

Sahakyan M, Harlow BL, Hornstein MD. Influence of age, diagnosis, and cycle number on pregnancy rates with gonadotropin-induced controlled ovarian hyperstimulation and intrauterine insemination. Fertil Steril. 1999. https://doi.org/10.1016/s0015-0282(99)00300-3.CrossRefPubMed

37.

Schorsch M, Gomez R, Hahn T, Hoelscher-Obermaier J, Seufert R, Skala C. Success rate of inseminations dependent on maternal age? An analysis of 4246 insemination cycles. Geburtshilfe Frauenheilkd. 2013. https://doi.org/10.1055/s-0033-1350615.CrossRefPubMedPubMedCentral

38.

Bedaiwy MA, Shokry M, Mousa N, Claessens A, Esfandiari N, Gotleib L, et al. Letrozole co-treatment in infertile women 40 years old and older receiving controlled ovarian stimulation and intrauterine insemination. Fertil Steril. 2009. https://doi.org/10.1016/j.fertnstert.2008.03.020.CrossRefPubMed

39.

Ibérico G, Vioque J, Ariza N, Lozano JM, Roca M, Llácer J, et al. Analysis of factors influencing pregnancy rates in homologous intrauterine insemination. Fertil Steril. 2004. https://doi.org/10.1016/j.fertnstert.2003.09.062.CrossRefPubMed

40.

Michau A, El Hachem H, Galey J, Le Parco S, Perdigao S, Guthauser B, et al. Predictive factors for pregnancy after controlled ovarian stimulation and intrauterine insemination: a retrospective analysis of 4146 cycles. J Gynecol Obstet Hum Reprod. 2019. https://doi.org/10.1016/j.jogoh.2019.05.006.CrossRefPubMed

41.

Bou Nemer L, Weitzman VN, Arheart KL, Barrionuevo MJ, Christie DR, Mouhayar Y, et al. In vitro fertilization versus mild stimulation intrauterine insemination in women aged 40 and older. Reprod Sci. 2017. https://doi.org/10.1177/1933719116667215.CrossRefPubMed

42.

Hull MGR, Eddowes HA, Fahy U, Abuzeid MI, Mills MS, Cahill DJ, et al. Expectations of assisted conception for infertility. Br Med J. 1996. https://doi.org/10.1136/bmj.304.6840.1465.CrossRef

43.

Nuojua-Huttunen S, Tomas C, Bloigu R, Tuomivaara L, Martikainen H. Intrauterine insemination treatment in subfertility: an analysis of factors affecting outcome. Hum Reprod. 1999. https://doi.org/10.1093/humrep/14.3.698.CrossRefPubMed

44.

Osaikhuwuomwan J, Osemwenkha A, Iribhogbe O, Aziken M, Orhue A. The effect of female age on the outcome of intrauterine insemination treatment in a public hospital-assisted reproduction technology unit. Niger J Clin Pract. 2018. https://doi.org/10.4103/njcp.njcp_248_16.CrossRefPubMed

45.

Houmard BS, Juang MP, Soules MR, Fujimoto VY. Factors influencing pregnancy rates with a combined clomiphene citrate/gonadotropin protocol for non-assisted reproductive technology fertility treatment. Fertil Steril. 2002. https://doi.org/10.1016/s0015-0282(01)02990-9.CrossRefPubMed

46.

Malchau SS, Henningsen AA, Loft A, Rasmussen S, Forman J, Nyboe Anderson A, Pinborg A. The long-term prognosis for live birth in couples initiating fertility treatments. Hum Reprod. 2017. https://doi.org/10.1093/humrep/dex096.CrossRefPubMed

47.

Frederick JL, Denker A, Rojas A, Horta I, Stone SC, Asch RH, et al. Is there a role for ovarian stimulation and intra-uterine insemination after age 40? Hum Reprod. 1994. https://doi.org/10.1093/oxfordjournals.humrep.a138438.CrossRefPubMed

48.

Vichinsartvichai P, Siriphadung S, Traipak K, Promrungrueng P, Manolertthewan C, Ratchanon S. The influence of women age and successfulness of intrauterine insemination (IUI) cycles. J Med Assoc Thai. 2015;98:833–8.PubMed

49.

Linara-Demakakou E, Bodri D, Wang J, Arian-Schad M, Macklon N, Ahuja K. Cumulative live birth rates following insemination with donor spermatozoa in single women, same-sex couples and heterosexual patients. Reprod Biomed Online. 2020. https://doi.org/10.1016/j.rbmo.2020.08.010.CrossRefPubMed

50.

De Brucker M, Camus M, Haentjens P, Verheyen G, Collins J, Tournaye H. Assisted reproduction using donor spermatozoa in women aged 40 and above: the high road or the low road? Reprod Biomed Online. 2013. https://doi.org/10.1016/j.rbmo.2013.02.008.CrossRefPubMed

51.

Kang BM, Wu TC. Effect of age on intrauterine insemination with frozen donor sperm. Obstet Gynecol. 1996. https://doi.org/10.1016/0029-7844(96)00074-9.CrossRefPubMed

52.

Auyeung A, Klein ME, Ratts VS, Odem RR, Williams DB. Fertility treatment in the forty and older woman. J Assist Reprod Genet. 2001. https://doi.org/10.1023/a:1013159116180.CrossRefPubMedPubMedCentral

53.

Buyalos RP, Daneshmand S, Peter MD, Brzechffa R. Basal estradiol and follicle-stimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy. Fertil Steril. 1997. https://doi.org/10.1016/s0015-0282(97)81514-2.CrossRefPubMed

54.

Corsan G, Trias A, Trout S, Kemmann E. Ovulation induction combined with intrauterine insemination in women 40 years of age and older: is it worthwhile? Hum Reprod. 1996. https://doi.org/10.1093/oxfordjournals.humrep.a019306.CrossRefPubMed

55.

Andersen AN, Gianaroli L, Felberbaum R, de Mouzon J, Nyren KG. Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE. Hum Reprod. 2006;https://doi.org/10.1093/humrep/del075.

56.

Belloc S, Cohen-Bacrie P, Benkhalifa M, Cohen-Barcie M, De Mouzon J, Hazout A, et al. Effect of maternal and paternal age on pregnancy and miscarriage rates after intrauterine insemination. Reprod Biomed Online. 2008. https://doi.org/10.1016/s1472-6483(10)60223-4.CrossRefPubMed

57.

Bonow MP, Donne RDD, da Rosa VB, Lucca JA, Hillesheim CM, Schuffner A. Intrauterine insemination as a primary viable option to infertile couples: evaluation of patients in a private center. J Bras Reprod Assist. 2019. https://doi.org/10.5935/1518-0557.20190014.CrossRef

58.

Campana A, Sakkas D, Stalberg A, Bianchi PG, Comte I, Pache T, et al. Intrauterine insemination: evaluation of the results according to the woman’s age, sperm quality, total sperm count per insemination and life table analysis. Hum Reprod. 1996. https://doi.org/10.1093/oxfordjournals.humrep.a019244.CrossRefPubMed

59.

Plosker SM, Jacobson W, Amato P. Predicting and optimizing success in an intra-uterine insemination programme. Hum Reprod. 1994. https://doi.org/10.1093/oxfordjournals.humrep.a138385.CrossRefPubMed

60.

Stone BA, Vargyas JM, Ringler GE, Stein AL, Marrs RP. Determinants of the outcome of intrauterine insemination: analysis of outcomes of 9963 consecutive cycles. Am J Obstet Gynecol. 1999. https://doi.org/10.1016/s0002-9378(99)70048-7.CrossRefPubMed

61.

Tay PYS, Mohan Raj VR, Kulenthran A, Sitizawiah O. Prognostic factors influencing pregnancy rate after stimulated intrauterine insemination. Med J Malaysia. 2007;62:286–9.PubMed

62.

Ashrafi M, Rashidi M, Ghasemi A, Arabipoor A, Daghighi S, Pourasghari P, et al. The role of infertility etiology in success rate of intrauterine insemination cycles: an evaluation of predictive factors for pregnancy rate. Int J Fertil Steril. 2013;7:100–7.PubMedPubMedCentral

63.

Khalil RM, Rasmussen PE, Erb K, Laursen SB, Rex S, Westergaard LG. Homologous intrauterine insemination. An evaluation of prognostic factors based on a review of 2473 cycles. Acta Obs Gynecol Scand. 2001. https://doi.org/10.1034/j.1600-0412.2001.800115.x.CrossRef

64.

Goldman MB, Thornton KL, Ryley D, Alper MM, Fung JL, Hornstein MD, et al. A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T). Fertil Steril. 2014. https://doi.org/10.1016/j.fertnstert.2014.03.012.CrossRefPubMedPubMedCentral

65.

Reindollar RH, Regan MM, Neumann PJ, Levine B, Thornton KL, Alper MM, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. Fertil Steril. 2010. https://doi.org/10.1016/j.fertnstert.2009.04.022.CrossRefPubMed

66.

Goverde AJ, McDonnell J, Vermeiden JP, Schats R, Rutten FF, Schoemaker J. Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysis. Lancet. 2000. https://doi.org/10.1016/S0140-6736(99)04002-7.CrossRefPubMed

67.

Morshedi M, Duran HE, Taylor S, Oehninger S. Efficacy and pregnancy outcome of two methods of semen preparation for intrauterine insemination: a prospective randomized study. Fertil Steril. 2003. https://doi.org/10.1016/s0015-0282(03)00250-4.CrossRefPubMed

68.

Soria M, Pradillo G, Garcia J, Ramón P, Castillo A, Jordana C, Paricio P. Pregnancy predictors after intrauterine insemination: analysis of 3012 cycles in 1201 couples. J Reprod Infertil. 2012;13:158–66.PubMedPubMedCentral

Titel: Ovulation induction and intrauterine insemination in women of advanced reproductive age: a systematic review of the literature
verfasst von: Carleigh B. Nesbit
Misty Blanchette-Porter
Navid Esfandiari
Publikationsdatum: 22.06.2022
Verlag: Springer US
Erschienen in: Journal of Assisted Reproduction and Genetics / Ausgabe 7/2022
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-022-02551-8

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Ovulation induction and intrauterine insemination in women of advanced reproductive age: a systematic review of the literature

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2022

Down syndrome live births following assisted reproductive technology in Japan: a nationwide survey between 2007 and 2016

Altered expression of Notch signaling, Tlr receptors, and surfactant protein expression after prostaglandin inhibition may be associated with the delayed labor in LPS-induced mice

Evaluation of placental growth potential and placental bed perfusion by 3D ultrasound for early second-trimester prediction of preeclampsia

Association between serum estradiol level on day of progesterone start and outcomes from frozen blastocyst transfer cycles utilizing oral estradiol

Fabrication on the microscale: a two-photon polymerized device for oocyte microinjection

The de novo aberration rate of prenatal karyotype was comparable between 1496 fetuses conceived via IVF/ICSI and 1396 fetuses from natural conception

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie